In the present study, we have investigated whether VEGFR‐1 might contribute to the acquisition of a BRAFi‐resistant phenotype by melanoma and whether blockade of this receptor might reduce ECM invasion by resistant tumour cells in response to angiogenic factors. This evidence concerns the gene FLT1 and neoplasm.